Two Sigma Advisers
QNCX icon

Two Sigma Advisers’s Quince Therapeutics QNCX Stock Holding History

Two Sigma Advisers’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-136
Closed -$90.8K – 1649
2025
Q4 		$90.8K Buy
+136
New +$68.4K ﹤0.01% 2238
2024
Q3 		– Sell
-468
Closed -$70.2K – 2480
2024
Q2 		$70.2K Sell
468
-18
-4% -$3.25K ﹤0.01% 2339
2024
Q1 		$103K Sell
486
-64
-12% -$15.9K ﹤0.01% 2302
2023
Q4 		$116K Sell
550
-110
-17% -$22K ﹤0.01% 2311
2023
Q3 		$148K Sell
660
-296
-31% -$77.3K ﹤0.01% 2153
2023
Q2 		$288K Sell
956
-1,069
-53% -$333K ﹤0.01% 1991
2023
Q1 		$632K Sell
2,025
-119
-6% -$23.3K ﹤0.01% 1845
2022
Q4 		$273K Sell
2,144
-155
-7% -$25.9K ﹤0.01% 2096
2022
Q3 		$611K Sell
2,299
-255
-10% -$97.1K ﹤0.01% 1757
2022
Q2 		$1.13M Buy
2,554
+22
+0.9% +$15.6K ﹤0.01% 1529
2022
Q1 		$3.13M Sell
2,532
-52
-2% -$70.8K 0.01% 1020
2021
Q4 		$6.52M Buy
2,584
+2,391
+1,239% +$14.6M 0.02% 656
2021
Q3 		$3.53M Buy
193
+146
+311% +$2.32M 0.01% 954
2021
Q2 		$498K Sell
47
-9
-16% -$75.5K ﹤0.01% 1936
2021
Q1 		$404K Buy
56
+6
+12% +$43.2K ﹤0.01% 2095
2020
Q4 		$275K Buy
+50
New +$443K ﹤0.01% 2070

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Advisers's QNCX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 136 shares — an estimated $90.8K sold.

Two Sigma Advisers first reported a position in QNCX in Q4 2020 and held it in 16 quarters. The position peaked at $6.52M in Q4 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 136 Quince Therapeutics shares in Q1 2026, an estimated $90.8K.
  • Two Sigma Advisers first reported a position in Quince Therapeutics in Q4 2020 and held it in 16 quarters.
  • Two Sigma Advisers's Quince Therapeutics position peaked at $6.52M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.